These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12534951)

  • 1. Aspects of cancer immunotherapy.
    McKenzie IF; Apostolopoulos V; Plebanski M; Pietersz GA; Loveland BE
    Immunol Cell Biol; 2003 Feb; 81(1):79-85. PubMed ID: 12534951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class I expression on human cancer cells. Implications for effective immunotherapy.
    Tait BD
    Hum Immunol; 2000 Feb; 61(2):158-65. PubMed ID: 10717809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of cellular immune responses to antigenic tumor peptides.
    Pietersz GA; Apostolopoulos V; McKenzie IF
    Cell Mol Life Sci; 2000 Feb; 57(2):290-310. PubMed ID: 10766024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
    Bodey B; Siegel SE; Kaiser HE
    In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
    Engelhard VH; Bullock TN; Colella TA; Mullins DW
    Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
    Adams EW; Ratner DM; Seeberger PH; Hacohen N
    Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
    de Charette M; Marabelle A; Houot R
    Eur J Cancer; 2016 Nov; 68():134-147. PubMed ID: 27755997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunobiology of dendritic cells and their application in clinical practice].
    Galamb O; Molnár B; Tulassay Z
    Orv Hetil; 2003 Sep; 144(38):1873-9. PubMed ID: 14596026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
    Wilkinson R; Kassianos AJ; Swindle P; Hart DN; Radford KJ
    Prostate; 2006 Feb; 66(2):180-92. PubMed ID: 16173035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
    Knutson KL; Disis ML
    Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review: dendritic cell immunotherapy for melanoma.
    Hadzantonis M; O'Neill H
    Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.
    Denkberg G; Reiter Y
    Autoimmun Rev; 2006 Apr; 5(4):252-7. PubMed ID: 16697965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects.
    Miura N; Akita H; Tateshita N; Nakamura T; Harashima H
    Mol Ther; 2017 Apr; 25(4):1003-1013. PubMed ID: 28236573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunoinformatics of cancer immunotherapy.
    Deluca DS; Blasczyk R
    Tissue Antigens; 2007 Oct; 70(4):265-71. PubMed ID: 17767547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour surveillance: missing peptides and MHC molecules.
    Khanna R
    Immunol Cell Biol; 1998 Feb; 76(1):20-6. PubMed ID: 9553772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.